Yang Xu

Dr. Yang Xu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2024 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
HLHao Lin
Hao Lin
ZGZhe Gao
Zhe Gao
TSTao Shan
Tao Shan
AAAyakuzi Asilebieke
Ayakuzi Asilebieke
RGRui Guo
Rui Guo
JCJian-Jun Chu
Jian-Jun Chu
Antibacterial bone cements (ABCs), such as antibiotic-loaded bone cements (ALBCs), have been widely utilized in clinical treatments. Currently, bone cements loaded with vancomycin, gentamicin, tobramycin, or clindamycin are approved by the US Food and Drug Administration. However, traditional ALBCs exhibit drawbacks like burst release and bacterial resistance. Therefore, there is a demand for the development of antibacterial bone cements containing novel agents to address these defects. In this review, we provide an overview and prospect of the new antibacterial agents that can be used or have the potential to be applied in bone cement, including metallic antibacterial agents, pH-switchable antibacterial agents, cationic polymers, N-halamines, non-leaching acrylic monomers, antimicrobial peptides and enzymes. Additionally, we have conducted a preliminary assessment of the feasibility of bone cement containing N-halamine, which has demonstrated good antibacterial activities. The conclusion of this review is that the research and utilization of bone cement containing novel antibacterial agents contribute to addressing the limitations of ALBCs. Therefore, it is necessary to continue expanding the research and use of bone cement incorporating novel antibacterial agents. This review offers a novel perspectives for designing ABCs and treating bone infections. Graphical abstract

4 August 2023 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
ZGZhe Gao
Zhe Gao
YXYang Xu
Yang Xu
YKYuchen Kan
Yuchen Kan
HLHailong Li
Hailong Li
RGRui Guo
Rui Guo
JCJianjun Chu
Jianjun Chu
Background: Non-leaching antibacterial bone cement can generate long-term antibacterial activity, it cannot treat serious infections that have occurred like antibiotic-loaded bone cement. Currently, the antibacterial activity and biocompatibility of non-leaching cement when loaded with antibiotics have yet to be determined. Methods: Non-leaching antibacterial nitrofuran bone cement (NFBC) specimens were prepared with low-dose and high-dose antibiotics. The antibacterial activity and biocompatibility of NFBC loaded with vancomycin, gentamicin, and tigecycline were compared. The agar diffusion method was employed to observe the inhibition zone of the samples against two bacterial strains from day one to day seven. The CCK-8 assay and acute liver and kidney toxicity test were conducted to assess the effects of the samples on mouse embryo osteoblast precursor cells and C57 mice, respectively. Results: Gentamicin-loaded cement exhibited the most potent antibacterial activity, effectively inhibiting both bacterial strains at a low dose. Tigecycline-loaded cement demonstrated superior biocompatibility, showing no acute liver and kidney toxicity in mice and minimal cytotoxicity to osteoblasts. Conclusions: NFBC loaded with gentamicin, vancomycin, and tigecycline not only maintains sustained antibacterial activity but also exhibits excellent biocompatibility.

4 April 2024 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
YXYang Xu
Yang Xu
HLHao Lin
Hao Lin
ZGZhe Gao
Zhe Gao
RGRui Guo
Rui Guo
YKYu-Chen Kan
Yu-Chen Kan
JCJian-jun Chu
Jian-jun Chu
A robust and easily manufactured high-strength and long-term release hydrazone-based isoniazid acrylic (HIA) bone cement is reported. The mechanical strength of HIA bone cement is similar to that of normal polymethyl methacrylate (PMMA) bone cement, far surpassing that of traditional isoniazid-containing antibiotic-loaded bone cement (INH bone cement). Isoniazid is connected to the bone cement through bioorthogonal hydrazone chemistry, and it possesses release properties superior to those of INH bone cement, allowing for the sustained release of isoniazid for up to 12 weeks. In vivo and in vitro studies also indicate that HIA cement exhibits better biocompatibility than INH bone cement. The results of this study not only signify progress in the realm of antimicrobial bone cement for addressing bone tuberculosis but also enhance our capacity to create and comprehend high-performing antimicrobial bone cement.

1 October 2023 in AIP Advances
Verified
Journal Article
Open access
PDF file
ZGZhe Gao
Zhe Gao
YKYu-Chen Kan
Yu-Chen Kan
YXYang-Hu Xie
Yang-Hu Xie
RGRui Guo
Rui Guo
CLChuang Li
Chuang Li
JCJian-Jun Chu
Jian-Jun Chu
Antibiotic-loaded bone cements are widely used in orthopedic surgery. However, they present issues such as a short antibiotic release time and antibiotic resistance. These challenges necessitate the development of novel antibacterial bone cements. Non-leaching bone cement containing antibacterial motifs represents a promising advancement in this direction. Antibacterial motifs are incorporated into the cement either covalently or non-covalently, and while they will not be released, they will still exhibit surface antibacterial activity. This review comprehensively examines the structure and antimicrobial activity of prevalent non-leaching antimicrobial bone cements. Additionally, it delves into the characteristics of current methods employed for detecting surface antimicrobial activity. Finally, the future research direction of non-leaching antibacterial bone cement is discussed, with a specific focus on innovative antibacterial motifs, the mechanisms underlying non-leaching antibacterial properties, and the potential synergies achievable by combining non-leaching antibacterial bone cement with traditional antibiotics.

3 October 2024 in Frontiers in Materials
Verified
Journal Article
Open access
PDF file
HLHao Lin
Hao Lin
ZGZhe Gao
Zhe Gao
LHLu-Yang Han
Lu-Yang Han
JCJian-jun Chu
Jian-jun Chu
YXYang Xu
Yang Xu
DSDian-Hong Shen
Dian-Hong Shen
A novel acrylic monomer containing a nitrofuran motif, referred to as long-chain nitrofuran methacrylate (LNFMA), is reported. In comparison to the previously reported nitrofuran methacrylate (NFMA), LNFMA has a longer side chain, and when incorporated into bone cement, the resulting LNFMA bone cement exhibits improved mechanical strength. At the same concentration, NFMA-5% cement has only 21.6 ± 1.3 MPa, while LNFMA-5% cement has a compressive strength of 42.64 ± 0.94 MPa. LNFMA bone cements exhibit antimicrobial activity against Staphylococcus aureus, with LNFMA-30% cement reaching 57.38% ± 5.53%. Moreover, LNFMA cement demonstrates excellent biocompatibility both in vitro and in vivo. The results showed that LNFMA monomer had optimized mechanical strength compared with previously reported NFMA monomers, and LNFMA bone cement had good antibacterial activity and biocompatibility.

9 January 2025 in RSC Advances
Verified
Journal Article
Open access
PDF file
WBWen-Han Bu
Wen-Han Bu
AAAyakuzi Asilebieke
Ayakuzi Asilebieke
LHLu-Yang Han
Lu-Yang Han
YXYang Xu
Yang Xu
TZTao Zhou
Tao Zhou
JCJian-jun Chu
Jian-jun Chu
A novel antibacterial non-leaching bone cement based 3,4-dichloro-5-hydroxyfuran-2(5 H )-one (DHF) was synthesized. We refer to it as DHF-MAA cement, and it exhibits excellent antibacterial activity, compressive properties, and biocompatibility.